Last reviewed · How we verify
NCT03791684
Accelerated Versus Standard CXL in the Treatment of Ectasia Post Refractive Surgery and Penetrating Keratoplasty.
NA trial testing Cross linking in Refractive Surgery in 111 participants. Completed in 26 June 2017.
16 January 2017
Quick facts
| Lead sponsor | Menoufia University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 111 |
| Start date | 16 January 2016 |
| Primary completion | 16 January 2017 |
| Estimated completion | 26 June 2017 |
Drugs / interventions tested
- Cross linking — full drug profile →
Conditions studied
- Refractive Surgery — all drugs for Refractive Surgery →
Sponsor
Menoufia University
Who can join
18 and older, any sex, with Refractive Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
WHAT WAS KNOWN \*Standard CXL is the common procedure for treating progressive corneal ectasia. Modifications of the standard protocol were introduces to reduce its complications especially long exposure to ultraviolet rays. The Accelerated protocol, while believed to overcome this issue with comparable outcomes, has not been studied fully in patients with ectasia following corneal refractive surgery and penetrating keratoplasty. WHAT THIS PAPER ADDS Accelerated CXL is as safe and effective as the Standard CXL in halting the progression of ectasia post refractive surgery and penetrating keratoplasty with the benefit of: reduced ultraviolet exposure, reduced operation time, and reduced patient discomfort.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Accelerated versus standard corneal cross linking in the treatment of ectasia post refractive surgery and penetrating keratoplasty: a medium term randomized trial.
Khairy HA, Elsawy MF, Said-Ahmed K, Zaki MA, et al · · 2019 · cited 7× · PMID 31741859 · DOI 10.18240/ijo.2019.11.08
Verify or expand the search:
- PubMed search for NCT03791684
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cross linking
Trials testing the same drug.
- NCT03429569 — Cross-Linking ACcéléré Iontophorèse Confocal kératocONE · Phase 4 · unknown
Other recruiting trials for Refractive Surgery
Currently open trials in the same condition.
- NCT07481487 — Outcomes of Cataract & Refractive Procedures · recruiting
- NCT07146828 — Clinical Application Research of 5-Degree (0.05 D) Precision Optometry in Corneal Refractive Surgery · NA · recruiting
- NCT06982807 — Clinical Study of SMILE 4.0-VISULYZE in Correcting Refractive Errors · NA · recruiting
- NCT06448468 — Analysis of Ocular Surface Microbiota in Dry Eye Patients After Femtosecond Laser-assisted In-situ Keratomileusis (FS-LA · recruiting
- NCT06264804 — Risk Factors for Progressive Suction Loss in Corneal Refractive Surgery · recruiting
Other Menoufia University trials
Trials by the same sponsor.
- NCT07522671 — Clinical Performance of 3D-Printed Resin and Zirconia Implant Restorations · NA · recruiting
- NCT07516236 — Dynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock · not yet recruiting
- NCT07485517 — Deep Versus Moderate Neuromuscular Blocking · NA · recruiting
- NCT07506044 — Dexmedetomidine as an Adjuvant During Dural Puncture Epidural · NA · recruiting
- NCT07322471 — Efficacy and Safety of Flexible Ureteroscopy Versus Percutaneous Nephrolithotomy in Management of Staghorn Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03791684 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Menoufia University
- Last refreshed: 4 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03791684.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing